Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14870589 | 0.91 | TYR (0.52) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL14870573 | 0.91 | KDM4E (0.55) | KDM4EALDH1A1POLBHPGDMAPT | |
| SCHEMBL14870581 | 0.88 | ACHE (0.51) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL1239258 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL1239255 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL14870574 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL14870580 | 0.84 | ALDH1A1 (0.52) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL2823209 | 0.84 | ALDH1A1 (0.51) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL2823206 | 0.84 | ALDH1A1 (0.51) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL14870582 | 0.83 | ALDH1A1 (0.52) | KDM4EALDH1A1POLBHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EIF2AK2, IRF3, IFNAR1 | SMN1; SMN2 3982/4885KDM4E 4372/4885ALDH1A1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.